Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   MDxHealth   /   Nieuws 2015

Nieuws 2015

Volgen
8.763 Posts
Pagina: «« 1 ... 179 180 181 182 183 ... 439 »» | Laatste | Omlaag ↓
  7. Johan Alverman 17 april 2015 18:33
    quote:

    JACKY CHAN schreef op 17 april 2015 12:19:

    Hou hier rekening mee dat april een correctiemaand is en MDxH zal even mee moeten. Ik schat een stand van 4.5 euro voor de cijfers.
    doe zoals deze meneer en verkoop alles want u kunt nu nog een goede prijs krijgen voor uw flutjes
  8. Cu Chulainn 17 april 2015 20:17
    Goldman Sachs downgrades their rating on the shares of EXACT Sciences Corporation (NASDAQ:EXAS). The current rating of the shares is Neutral. Earlier, the shares were rated a Buy by the brokerage firm. Equity Analysts at the Firm lowers the price target to $24 per share from $29 per share.
  9. Niks is wat het lijkt 17 april 2015 22:57
    quote:

    Cu Chulainn schreef op 17 april 2015 20:17:

    Goldman Sachs downgrades their rating on the shares of EXACT Sciences Corporation (NASDAQ:EXAS). The current rating of the shares is Neutral. Earlier, the shares were rated a Buy by the brokerage firm. Equity Analysts at the Firm lowers the price target to $24 per share from $29 per share.
    Lekker nuttige info. Bericht van 26 maart.......
  10. J_2000 18 april 2015 07:06
    quote:

    Niks is wat het lijkt schreef op 17 april 2015 22:57:

    [...]

    Lekker nuttige info. Bericht van 26 maart.......
    Was gisteren opnieuw verschenen op een nieuwssite..
    En inderdaad, downgrade is van 26 maart, maar waar GS wel aangaf dat ze blijven geloven in Cologuard..Enkel dat oorspronkelijke lancering & kosten eerder wat onderschat waren..
  11. sons123 19 april 2015 13:10
    quote:

    JACKY CHAN schreef op 17 april 2015 12:19:

    Hou hier rekening mee dat april een correctiemaand is en MDxH zal even mee moeten. Ik schat een stand van 4.5 euro voor de cijfers.
    Ben benieuwd nu bekent is dat Rusland Griekenland onrechtstreeks toch financieel gaat steunen door een pijplijn te trekken door Griekenland naar Europa,dit geen weerslag gaat hebben op de koersen volgende week.?
  13. Johan Alverman 19 april 2015 17:02
    quote:

    vreemd vermogen schreef op 19 april 2015 13:22:

    Zo de miljardjes vliegen weer om je oren. Heeft Teva geen interesse in MDx?
    www.iex.nl/Nieuws/ANP_ANP-190415-076/...
    Uw billekes zijn samengeknepen en angst overheerst en u hoopt snel uit uw lijden verlost te worden helaas geen enkele interesse voor mdxh alleen maar lagere koersen
  15. peebee 19 april 2015 22:12
    quote:

    lordonehope schreef op 19 april 2015 17:02:

    [...]

    Uw billekes zijn samengeknepen en angst overheerst en u hoopt snel uit uw lijden verlost te worden helaas geen enkele interesse voor mdxh alleen maar lagere koersen
    Lord, waarom zit jij op dit forum?
    heb je zelf aandelen, ja of nee..

    ben gewoon benieuwd....
  16. [verwijderd] 20 april 2015 08:23
    Press Release
    MDxHealth Completes Enrollment of Second ConfirmMDx Clinical Utility Study

    PASCUAL Study Expected to Support Expanded Reimbursement

    IRVINE, CA, and HERSTAL, BELGIUM - April 20, 2015 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has completed patient enrollment into its prospective, randomized PASCUAL clinical utility study with ConfirmMDx® for Prostate Cancer. The study, which will evaluate the impact of the ConfirmMDx test results on physician decisions for repeat biopsy, enrolled 600 patients from 17 leading urology practices across the U.S.

    "We are pleased with the rapid enrollment of patients into the PASCUAL study, which illustrates the need for a novel biomarker like ConfirmMDx to assist with clinician-patient decisions concerning a repeat prostate biopsy," stated principal investigator Neal Shore, M.D. Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina. "Completing enrollment of the study ahead of schedule is an early indication of the importance of this test for urologists and their patients."

    "Medicare coverage for ConfirmMDx for Prostate Cancer is a significant achievement for the company and we are committed to taking all the steps necessary to ensure continued and expanded availability to men suspected of harboring prostate cancer," noted Dr. Jan Groen, CEO of MDxHealth. "In today's value-based healthcare environment, well-designed clinical utility studies are required to demonstrate improved patient outcomes and gain insurance coverage, which in the end provides patients with access to these important tests."

    The ConfirmMDx for Prostate Cancer test, which helps urologists identify low risk men who may forego unnecessary repeat biopsy procedures, qualified for Medicare coverage on November 3, 2014. MDxHealth is conducting the PASCUAL study and enrolling providers into its Certification and Training Registry as part of an ongoing commitment to ensure appropriate use of the ConfirmMDx test, in line with the LCD providing coverage of the test. If the interim analysis demonstrates a substantially lower repeat biopsy rate, Palmetto GBA will expand physician participation in the ConfirmMDx Registry, effectively increasing the number of Medicare patients covered. Unrestricted Medicare coverage, with the Registry requirement removed, is expected upon publication of favorable PASCUAL study results when the study is concluded.

    About ConfirmMDx® for Prostate Cancer

    Up to 1 million American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores sample less than 1% of a man's prostate. This approach leaves men at risk of undetected cancer, leading to a high rate of repeat biopsies, even on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or "halo" associated with the cancerization process at the DNA level. This "halo" around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure. Performance of the proprietary ConfirmMDx genes and technology has been published in 45 studies on over 5,000 patients tested. The ConfirmMDx test has qualified for Medicare reimbursement as of November 3, 2014 and is also available to more than 152 million insured lives via private health insurance plans.

    About MDxHealth

    MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

    For more information:

    Dr Jan Groen, CEO Mike Sinclair
    MDxHealth Halsin Partners
    US : +1 949 812 6979 UK: +44 20 7318 2955
    BE: +32 4 364 20 70 Cell: +44 7968 022075
    info@mdxhealth.com msinclair@halsin.com
    This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

    NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

    English version

    Version Française
  17. [verwijderd] 20 april 2015 08:56
    de belangrijkste zinnen uit die PR:
    1. PASCUAL Study Expected to Support Expanded ReimbursementIf the interim analysis demonstrates a substantially lower repeat biopsy rate,
    2. Palmetto GBA will expand physician participation in the ConfirmMDx Registry, effectively increasing the number of Medicare patients covered. Unrestricted Medicare coverage, with the Registry requirement removed, is expected upon publication of favorable PASCUAL study results when the study is concluded.
    Deze goedkeuring zou wel eens sneller kunen komen dan we denken en dan is deze prostaattest een echte goudmijn!
8.763 Posts
Pagina: «« 1 ... 179 180 181 182 183 ... 439 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum